S troke is the third most common cause of death in many developed countries, and ≈80% of strokes are ischemic in origin. 1, 2 In South Korea, stroke is the most frequent cause of death after cancer and is more frequent than heart disease. 3 Multiple factors, including hypertension, diabetes mellitus, smoking, hyperlipidemia, and hyperhomocysteinemia, are associated with a higher risk of stroke. 2 Silent brain infarction (SBI) is defined as a cerebral infarction evident by brain imaging, but without a clinical syndrome. SBI is characterized by the rapid development of clinical symptoms, as well as focal or global loss of brain function. SBIs are common with advanced age. 4 Although the clinical significance of SBI remains controversial, its presence can predict widespread vascular damage, such as a clinically overt stroke. 5 Based on several lines of evidence, hyperhomocysteinemia is thought to be an independent risk factor for SBI. [6] [7] [8] Other metabolic syndromes, including hypertension and impaired fasting glucose, are also common SBI risk factors. 4, 9, 10 MicroRNAs (miRNAs) are a class of endogenous, small, noncoding RNAs that pair with sites in 3ʹ-untranslated regions in mRNAs to downregulate their expression. 11 MiRNAs are initially transcribed by RNA polymerase II in the nucleus to form large pri-miRNA transcripts. The pri-miRNAs are processed by the RNase III enzymes, Drosha and Dicer, to generate 18-to 24-nucleotide mature miRNAs. 11 The recent discovery of miRNAs as key regulators of gene function has introduced a new level and mechanism of gene regulation. 12, 13 Although there are only few hundreds of miRNAs, each miRNA can potentially regulate hundreds of target genes, 14 with the prediction that more than one third of all human genes may be regulated by miRNAs. MiRNA expression has been examined in various tumors, [14] [15] [16] Alzheimer disease, Parkinson disease, 17 Down syndrome, 18 schizophrenia, 19 and stroke. 20, 21 Recently, 4 well-known miRNA polymorphisms in pre-miRNA sequences (miR-146aC>G [rs2910164; chromosome 5, 159912418] , miR-149T>C [rs2292832; chromosome 2, 241395503], miR-196a2T>C [rs11614913; chromosome 12, 54385599] , and miR-499A>G [rs3746444; chromosome 20, 33578251]) have been studied in a variety of diseases and were found to contribute to pathogenesis. [22] [23] [24] [25] [26] According to recent data, the miR-146aG, miR-149T, miR-196a2C, and miR-499G alleles are possible genetic predisposing
Genetic Analyses
We extracted DNA from leukocytes using the G-dex II Genomic DNA Extraction Kit (iNtRON Biotechnology, Seongnam, South Korea), according to the manufacturer's instructions. We used PCRrestriction fragment length polymorphism (RFLP) assays to analyze the miR-146aC>G, miR-196a2T>C, and miR-499A>G polymorphisms. Genotyping of the miR-149T>C polymorphism was determined using real-time PCR (RG-3000, Corbett Research, Australia) for allelic discrimination. Primers and TaqMan probes were designed using Primer Express Software (version 2.0), and synthesized and supplied by Applied Biosystems (United States). The reporter dyes used were 5-carboxyfluorescein (FAM) and 2',7'-dimethoxy-4',5'dichloro-6-carboxyfluorescein (JOE). The primer sequences for amplification are as follows: miR-146aC>G: forward 5ʹ-CAT GGG TTG TGT CAG TGT CAG AGC T-3ʹ and reverse 5ʹ-TGC CTT CTG TCT CCA GTC TTC CAA-3ʹ; and miR-149T>C: forward 5ʹ-CTG GCT CCG TGT CTT CAC TC-3ʹ and reverse 5ʹ-CAA CTC GCC CAG CCG-3ʹ. The selected probes were 5ʹ-FAM-TGG GGC AGC CGG AAC AAC-TAMRA-3ʹ (C allele detecting probe) and 5ʹ-JOE-TGG GGC AGC TGG AAC AAC-TAMRA-3ʹ (T allele detecting probe); miR-196a2T>C: forward 5ʹ-CCC CTT CCC TTC TCC TCC AGA TA-3ʹ and reverse 5ʹ-CGA AAA CCG ACT GAT GTA ACT CCG-3ʹ; and miR-499A>G: forward 5ʹ-CAA AGT CTT CAC TTC CCT GCC A-3ʹ and reverse 5ʹ-GAT GTT TAA CTC CTC TCC ACG TGA TC-3ʹ (contains a mismatch sequence). The miR-146aC>G and miR-196a2T>C polymorphisms were digested by SacI and MspI, respectively, for 16 hours at 37°C (New England BioLabs, Beverly, MA). The 499A>G polymorphism was digested with BclI for 16 hours at 50°C (New England Biolabs). The PCR annealing temperature was 58°C for all polymorphisms, with 50 amplification cycles for miR-149T>C. The reaction product (12 µL) was run on a 3.0% ethidium bromide-stained agarose gel and directly visualized under ultraviolet illumination. We randomly repeated approximately 10% of the PCR assays for each of the miRNA polymorphisms and checked the results for concordance by DNA sequencing using an automatic sequencer (ABI3730x l DNA analyzer; Applied Biosystems, Foster City, CA). The concordance of the quality control samples was 100%.
Measurement of Plasma Total Homocysteine and Folate Levels
We collected plasma samples to measure total homocysteine (tHcy) and folate levels within 48 hours of stroke onset or SBI detection. Twelve hours after the patient's previous meal, we collected whole blood in a tube containing anticoagulant. We centrifuged the tube for 15 minutes at 1000g to separate the plasma. We measured the plasma tHcy concentration using a fluorescent polarizing immunoassay with the IMx system (Abbott Laboratories, Chicago, IL), and the plasma folate concentration with a radio assay kit (ACS 180; Bayer, Tarrytown, NY).
Statistical Analyses
To estimate the relative risk of the various genotypes for stroke and SBI, the odds ratio (OR) and 95% confidence interval (CI) were calculated. Case and control groups were compared using a Student t test for continuous variables, and the χ 2 test for categorical variables. For multivariate analyses, logistic regression analyses were used to adjust for possible confounders, including age, sex, hypertension, diabetes mellitus, hyperlipidemia, and smoking. Statistical significance was accepted at the P<0.05 level.
We performed multiple hypotheses testing using the Benjamini-Hochberg method to control for false discovery rate in the logistic regression analysis. Calculating the false discovery rate is a way to address the problems associated with multiple comparisons, and false discovery rate provides a measure of the expected proportion of false-positives among data. Analyses were performed using GraphPad Prism 4.0 (GraphPad Software, Inc., San Diego, CA), StatsDirect Statistical Software Version 2.4.4 (StatsDirect Ltd., Altrincham, UK), and Medcalc (Version 7.4 for Windows; Mariakerke, Belgium).
The multifactor dimensionality reduction (MDR) method was proposed by Ritchie et al 34 and Moore and William, 35 and implemented by Hahn et al 36 and Ritchie et al. 37 The MDR method has been described in detail previously. [34] [35] [36] [37] Briefly, the MDR is comprised of 2 steps. First, the best combination of multifactors is chosen. Second, the genotype combinations are classified into highand low-risk groups. 38 Interaction analyses were performed in the open-source MDR software package (v.2.0) available from www. epistasis.org. Using MDR analyses, we constructed all possible allele combinations for gene-gene interactions. HAPSTAT software was used to estimate the frequencies of allele combinations for the polymorphisms selected by MDR analysis with strong synergistic effects. HAPSTAT allows testing of the haplotype (or allele combination) effects by maximizing the likelihood (from the observed data) that properly accounts for phase uncertainty and study design. Current versions of the HAPSTAT software (v.3.0) are available from the www.bios.unc.edu/~lin/hapstat/.
Results

Study Population
The characteristics of patients with ischemic stroke and SBI, and the control groups are summarized in Table 1 . Ischemic stroke patients were significantly more likely to smoke, as well as have high-density lipoprotein cholesterol, diabetes mellitus, hypertension, hyperlipidemia, increased tHcy levels, and decreased folate levels (P<0.05).
Genotype Frequencies of the MiRNA Polymorphisms
We investigated the miR-146aC>G, 149T>C, 196a2T>C, and 499A>G polymorphisms. Table 2 shows their genotype distributions in ischemic stroke and SBI patients and control subjects. We calculated the adjusted odds ratio (AOR) from logistic regression analyses with respect to age, sex, hypertension, diabetes mellitus, smoking, and hyperlipidemia. The miRNA genotype frequencies of controls were consistent with the Hardy-Weinberg equilibrium expectations. The miR-146aC>G polymorphism was significantly different between the ischemic stroke patients and control group (CC versus GG: AOR, 1.583, 95% CI, 1.104 -2.270; CC+CG versus GG: AOR, 1.444, 95% CI, 1.047 -1.991; C allele versus G allele: AOR, 1.244, 95% CI, 1.051 -1.472). However, the miR-149T>C, miR-196a2T>C, and miR-499A>G polymorphisms were not significantly different between stroke patients and control subjects. Furthermore, the relationship between SBI susceptibility and miRNA polymorphisms could not be established (Table 2 ).
Subtype Analyses of Ischemic Stroke
To examine whether the effect of each polymorphism is confined to a specific subtype or related to generalized risk, we further separated the stroke group into 2 subgroups (LAD and SVD) according to the Trial of Org 10172 in Acute Stroke Treatment classification. In subgroup analyses, LAD was significantly associated with the miR-146aC>G polymorphism (CC versus GG: AOR, 1.588, 95% CI, 1.002 -2.516; CC+CG versus GG: AOR, 1.681; 95% CI, 1.109 -2.547). Additionally, comparison of SVD showed differences with the control subjects (CC versus CG: AOR, 1.769, 95% CI, 1.176 -2.661; CC versus CG+GG: AOR, 1.683, 95% CI, 1.136 -2.495). The miR-149T>C showed significant association with the SVD type (TT versus CC: AOR, 2.069, 95% CI, 1.185 -3.612; TT+TC versus CC: AOR, 1.930, 95% CI, 1.156 -3.223; T allele versus C allele: AOR, 1.340, 95% CI, 1.032 -1.739; Table 3 ).
Gene-Gene Interaction Analyses Using the MDR Method
We constructed possible allele combinations of miR-146a, miR-149, miR-196a2, and miR-499 to analyze gene-gene in teractions ( Table 4 ). As a result, miR-146a/-149/-196a2/-499, miR-146a/-196a2/-499, and miR-146a/-196a2 Table 1 
. Baseline Characteristics of Ischemic Stroke Patients and SBI Patients and Control Subjects
Subgroup Analyses
To determine additional clinical significance, we performed stratified analyses according to age, sex, hypertension, diabetes mellitus, and hyperlipidemia. In the stratified analyses, we found that the miR-146aCG+GG genotypes showed significant increases in the incidence of ischemic stroke compared with the CC genotype in the female (CC versus CG+GG: AOR, 1.431, 95% CI, 1.022-2.002), normotensive (CC versus CG+GG: AOR, 1.632, 95% CI, 1.133 -2.350), and nondiabetic subgroups (CC versus CG+GG: AOR=1.355, 95% CI, 1.028 -1.785). Furthermore, the miR-149T>C polymorphism was connected to ischemic stroke risk in the female (TT versus TC+CC: AOR, 1.405, 95% CI, 1.017 -1.943) and nondiabetic subgroups (TT versus TC+CC: AOR, 1.300, 95% CI, 1.001 -1.688; Table 5 ). For SBI, the miR-499AG+GG genotype was associated with an increased risk of SBI in the male subgroup (AA versus AG+GG: AOR, 1.680, 95% CI, 1.102 -2.559; Table 6 ).
Combined Effects Between miRNA Polymorphisms and tHcy/Folate Levels on Disease Prevalence
To investigate the gene-environment interaction, we analyzed the combined effects between miRNA polymorphisms and tHcy/folate levels. Generally, high-tHcy and low-folate levels increase the prevalence of stroke. We divided subjects into 2 groups according to the upper and lower 15% cutoff values of plasma tHcy and folate levels, respectively (stroke: 13.9 μmol/L, 3.43 ng/mL; SBI: 13.4 μmol/L, 4.46 ng/mL). There were significant combined gene-environment effects (Table 7) .
Supplemental Data
We analyzed the genotype data of young and middle-aged samples to investigate whether there were any strong genetic predisposing effects (Tables I-III in the online-only Data  Supplement) . Some variants and allele combinations showed significant associations. However, the meaning of these associations should be interpreted with caution because the sample size is rather small. Tables IV-VII in 
Discussion
MiRNAs play important roles in many physiological and pathological processes, including tumorigenesis, 15 proliferation, 39 hematopoiesis, 40 metabolism, 41 immune function, 42 epigenetics, and neurodegenerative diseases. 43 MiRNAs are also useful in identifying the pathogenesis of lymphoma, 44 and the progression MDR indicates multifactor dimensionality reduction; OR, odds ratio; SBI, silent brain infarction; LAD, large-artery disease; and SVD, small-vessel disease. 43 Emerging evidence has indicated circulating miRNAs may be novel biomarkers for cardiovascular diseases, including acute myocardial infarction, heart failure, coronary artery disease, diabetes mellitus, stroke, essential hypertension, and acute pulmonary embolism. 21, [45] [46] [47] [48] Globally, there are >50 million stroke patients, producing an immense burden on the economic and healthcare infrastructure. 49 An miRNA profile under ischemic conditions from the brain and blood of rats subjected to middle cerebral artery occlusion was performed and indicated that studies are needed to evaluate the possibility of using circulating miRNAs as biomarkers in stroke and related pathologies. 21 An miRNA array was therefore used to identify the miRNA signature in peripheral blood of patients with ischemic stroke. 49 An miRNA expression profile was implicated in endothelial/vascular function, erythropoiesis, angiogenesis, and neural function, demonstrating the potential of using peripheral blood miRNA profiles as biomarkers of cerebral ischemic stroke. 50 Similar to the use of cardiac-specific miRNA as biomarkers of acute myocardial infarction, the concentration of the brain-specific miR-124 was also reported to be increased in the plasma of a rat acute ischemic stroke model, garnering interest in exploring brain-specific miRNAs, including miR-124, miR-134, miR-153, miR-9, and miR-219, as potential plasma biomarkers of human acute ischemic stroke. 47 However, few reports are available on the roles of miRNAs in ischemic stroke and SBI. To our knowledge, this is the first study to provide evidence that 4 miRNA polymorphisms play roles in the predisposition of the Korean population to ischemic stroke and SBI. In this study, we investigated the miR-146aC>G (rs2910164), miR-149T>C (rs2292832), miR-196a2T>C (rs11614913), and miR-499A>G (rs3746444) polymorphisms on ischemic stroke and SBI.
The 4 miRNAs we studied are closely associated with vascular damage responses. The miR-146a, -149, -196a2, and -499 can regulate TNF-α, 27 methylenetetrahydrofolate reductase, 28 ANXA1, 29 and CRP, 30 respectively. According to previous reports, TNF-α, methylenetetrahydrofolate reductase, ANXA1, and CRP were general causes of cerebral ischemia. [51] [52] [53] [54] TNF-α is associated with increased plasminogen activator inhibitor-1 protein levels, 55 methylenetetrahydrofolate reductase dysfunction is related to plasma tHcy accumulation, 56 ANXA1 is connected to decreased TNF-α levels, 57 and CRP can elevate blood pressure, body mass index, insulin resistance, and triglycerides. 58 CRP and TNF-α are simultaneously activated in stress conditions. 59 These data suggest that TNFα, ANXA1, and CRP may be closely linked. In fact, MDR analyses in the present study indicated genetic interaction of miR-146a/-196a2/-499 and miR-146a/-196a2. There have been studies on the functionalities of miRNA polymorphisms, despite restrictive data. The miR-146aG and miR-196a2T allele are associated with decreased mature miRNA levels. 60, 61 There was no mature miRNA expression, according to miR-149T>C and miR-499A>G. However, miR-499AA is associated with decreased plasma CRP concentrations. 30 Based on these results, we suspect miR-146aC, miR-196a2T, and miR-499A alleles have protective roles in stroke pathogenesis through inhibition of TNF-α and CRP levels. However, we were unable to measure miRNA, TNF-α, and CRP levels in the present study. MiRNA indicates microRNA; tHcy, total homocysteine; SBI, silent brain infarction; AOR, adjusted odds ratio; and 95% CI, 95% confidence interval. We divided subjects into 2 groups according to the upper and lower 15% cutoff values of plasma tHcy and folate levels, respectively (stroke: 13.9 μmol/L, 3.43 ng/mL; SBI: 13.4 μmol/L, 4.46 ng/mL).
There are several limitations of the present study: (1) As noted, it is not yet clear which genetic polymorphisms predict the phenotypes associated with ischemic stroke and SBI. Our study population comprised only Korean individuals, and our findings will need to be validated in other ethnic groups. (2) This was a hospital-based case-control study that had a relatively small sample size of individual stroke subtypes. However, the recruitment of >1000 individuals from an ethnically homogeneous population (Koreans have a low degree of interracial marriage) is enough to give reliable data.
(3) Control subjects were not recruited from a completely healthy population because some of them were seeking medical attention. Those who agreed to diagnostic evaluation differed from those who did not agree. Therefore, it is not easy to identify the casual effects of vascular risk factors in these subjects. Therefore, based on selection bias, our results may underestimate the true impact of individual risk factors. However, in our experience, the recruitment of healthy participants markedly reduces recruitment rates because of their refusal to undergo laboratory and imaging studies. Interview-dependent risk factor assessment (without laboratory and imaging studies) may fail to find covert risk factors and asymptomatic lesions (for example, SBI), thus leading to another potential for bias. In the present study, ≈6% of the study subjects were found to have a new vascular risk factor through laboratory tests at the time of examination. All of our study subjects had brain imaging and were confirmed to be negative for symptomatic brain lesions, thereby enhancing the diagnostic accuracy and exact case-control grouping. Although a population-based study may be optimal to reduce the referral or selection bias, it is difficult to obtain sufficient numbers of stroke incidents because the estimated annual incidence of stroke is low in the general population. (4) Finally, our results cannot be extrapolated to other races because interethnic variability in the frequency of stroke subtypes and genotypes may produce different results.
In conclusion, the G allele of the miR-146a polymorphism was associated with an increased risk of ischemic stroke in the Korean population. This study marks the first report of an association between stroke and SBI, and miRNA polymorphisms (miR-146aC>G, -149T>C, -196a2T>C, -499A>G) in the Korean population. Therefore, additional studies of other racial and ethnic populations regarding the biological functions of miRNA are needed to fully understand the role of miRNA polymorphisms in ischemic stroke and SBI risk. 
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